Fair Value Measurements - Additional Information (Detail)	12 Months Ended
	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 USD ($) shares	Sep. 30, 2015 USD ($)	Sep. 30, 2011 shares	Jan. 31, 2013 shares	Dec. 31, 2012 shares	Jun. 30, 2010 shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	432,284
Derivative liability remaining | $	$ 695,114	$ 1,602,626
Contingent consideration obligations | $	0	$ 0
Exchange rights | Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding		500,000
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ 19,602	$ (7,950)	$ 184,555
Duration of exchange rights	7 years
Exchange right convertible conversion ratio	0.01
Number of exchange rights exercised	500,000			675,000
Derivative liability remaining | $	$ 0
2010 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock							329,649
Warrants cancelled upon expiration		24,324
2012 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock						912,543
Warrants outstanding	265,161
2013 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock					833,530
Warrants outstanding	12,123
Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ 870,760	$ (293,072)	$ 2,684,712